FORM 8-K

Current report filing

Filing Date: **1998-07-22** | Period of Report: **1998-07-16**
SEC Accession No. 0001012975-98-000189

FILER

CELGENE CORP /DE/

CIK:**816284**| IRS No.: **222711928** | State of Incorp.:**DE** | Fiscal Year End: **1231**
Type: **8-K** | Act: **34** | File No.: **000-16132** | Film No.: **98669577**
SIC: **8731** Commercial physical & biological research

Mailing Address
7 POWDER HORN DRIVE
P O BOX 4914
WARREN NJ 07059

Business Address
7 POWDER HORN DR
WARREN NJ 07059
9082711001

==========

United States
Securities and Exchange Commission
Washington, D.C. 20549

FORM 8-K

Current Report
Pursuant to Section 13 OR 15(d) of the
Securities Exchange Act of 1934

July 16, 1998	0-16132
Date of Report	Commission File Number
(Date of earliest event reported)	

Celgene Corporation
(Exact name of registrant as specified in its charter)

Delaware	22-2711928
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification Number)

7 Powder Horn Drive
Warren, New Jersey 07059

(Address of Principal Executive Offices) (Zip Code)

(732) 271-1001

(Registrant's telephone number, including area code)

==========

Item 5. Other Events.

On July 16, 1998, Celgene Corporation (the "Company") received clearance from the U.S. Food and Drug Administration to market and sell Thalomid (TM)(Thalidomide)for the treatment of erythema nodosum leprosum (ENL), a severe and debilitating condition associated with leprosy.

Item 7. Financial Statements, Unaudited Pro Forma Financial Information and Exhibits.

(a) Not applicable.

(b) Not applicable

(c) Exhibits

99 Press Release, dated July 16, 1998.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 21, 1998 CELGENE CORPORATION

By: /s/ John W. Jackson
Name: John W. Jackson
Title: Chairman of the Board and Chief Executive Officer

EXHIBIT 99

HEADLINE: Celgene Announces FDA Clears Thalidomide For Sale in U.S.

DATELINE: WARREN, N.J., July 16

BODY:

Celgene Corporation (Nasdaq: CELG) today announced it has received clearance from the U.S. Food and Drug Administration (FDA) to market and sell THALOMID (TM) (thalidomide) for the treatment of erythema nodosum leprosum (ENL), a severe and debilitating condition associated with leprosy.

Celgene licensed rights to thalidomide from The Rockefeller University in 1992 and began developing the drug for a range of potential indications. These include AIDS related, dermatological and cancer related conditions. Celgene submitted a new drug application (NDA) for THALOMID (TM) in December 1996.

"Making THALOMID (TM) available to the American people required a concerted and cooperative effort between Celgene and the FDA," said Celgene's Chairman and Chief Executive Officer, John W. Jackson. "Celgene is committed to the continued development of THALOMID (TM) as a therapy for people suffering from serious and debilitating diseases."

In order to support the safe and appropriate use of the drug, Celgene has developed a unique and comprehensive patient, physician and pharmacist education and distribution system to be called the System for Thalidomide Education and Prescribing Safety (STEPS).

Celgene Corporation, headquartered in Warren, NJ, is engaged in the development of human pharmaceuticals and agrochemicals.

This release contains certain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or other expectations implied by these forward-looking statements. These factors include results of current or pending clinical trials, actions by the FDA and other regulatory authorities, and those factors detailed in the Company's filings with the Securities and Exchange Commission.